Navigation Links
Lupus Foundation of America Statement on Results for Clinical Study,of CellCept Released by Aspreva Pharmaceutical Company

overall improvement in care for lupus nephritis patients. In line with this, the LFA is eager to see some subset analysis, for example, an analysis of how CellCept performs in patients of African descent, since IVC is known to be less effective for this population.

The preliminary data from Aspreva suggest that overall incidence of side effects were the same for CellCept and IVC. This is expected when all major and minor side effects are counted equally. However, there is a large body of published literature with convincing evidence that CellCept is better tolerated, and, more importantly to patients and their doctors, is associated with fewer serious or life-threatening infections, and hospitalizations. IVC is also linked to a high incidence of infertility, which is not the case with CellCept. We eagerly await further data from this new trial on these kinds of side effects, which patients and doctors are most concerned about.

The results released today are only preliminary findings. The LFA looks forward to further analysis of the data and will report this information as soon as it becomes available.

About the LFA: The Lupus Foundation of America is the nation's leading nonprofit voluntary health organization dedicated to finding the causes and cure for lupus. The LFA and its nationwide network of nearly 300 chapters, branches and support groups operate programs of research, education, support and advocacy.

CONTACT: Duane Peters of Lupus Foundation of America, Inc.,+1-202-349-1145

Web site: http://www.lupus.org//

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2

Related medicine technology :

1. Aspreva and Roche Announce Preliminary Results for Phase III Study Evaluating CellCept in Lupus Nephritis
2. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
3. Cellerant Therapeutics Reversed Autoimmune Disease in Lupus Mice with Transplant of Purified Donor Blood Stem Cells
4. La Jolla Pharmaceutical Provides Update on Interim Antibody Results From Riquent Lupus Phase 3 Trial
5. La Jolla Pharmaceutical Announces Positive Interim Antibody Results From Riquent Lupus Phase 3 Trial
6. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
7. The Christopher and Dana Reeve Foundation Expresses Disappointment Over President Bushs Veto of the Stem Cell Research Enhancement Act
8. Hypertension Education Foundation Survey Results Announced At American Society For Hypertension Annual Meeting Suggests Improved Control Of High Blood Pressure, But Misconceptions Still Exist
9. The International Myeloma Foundation Reports Positive Shift In Treatment Paradigm For Patients
10. Research Supported by Samuel Waxman Cancer Research Foundation Discovers Mode of Action of Arsenic-Based Drugs in Destroying Cancer Cells
11. The International Myeloma Foundation Says New Clinical Trial Results Could Improve Survival While Reducing Side Effects For Many Patients

Post Your Comments:
(Date:11/6/2009)...PRNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq: ...ping products for minimally disruptive surgical tr...tment of Michael J. Lambert as Executive Vice Pres...ber 9, 2009. The Company also announced several o...hael will be an excellent complement to the NuVasi...
(Date:11/6/2009)... Nov. 6 With his proposed health c...s sights on cutting name-brand prescription drug c...into the "Part D" coverage gap, universally known ... potential cost-cutting and feel it,s a promising ...powerful lobbyists want a revised program that com...
(Date:11/6/2009)...Newswire-FirstCall/ -- Cyberonics, Inc. (Nasdaq: ...t financial results for the second quarter ended O..., 2010 on Wednesday, November 18, 2009 at 5:00 PM ...o discuss those results on Thursday, November 19, ...nd Quarter Results Conference Call Instructions ...
Breaking Medicine Technology:NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 2NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 3NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 4NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 5Obama Healthcare Reforms Fall Short, but Betterthanmedicare.com Closes the 'Donut Hole' 2Obama Healthcare Reforms Fall Short, but Betterthanmedicare.com Closes the 'Donut Hole' 3Cyberonics Announces Conference Call to Discuss Fiscal Year 2010 Second Quarter Financial Results 2Motion analysis helps soccer players get their kicks 51204 1Motion analysis helps soccer players get their kicks 51204 2Motion analysis helps soccer players get their kicks 51204 3Landmark project to map genomics of complex ant systems 9188 1Landmark project to map genomics of complex ant systems 9188 2Spread your sperm the smart way 9186 1Spread your sperm the smart way 9186 2Spread your sperm the smart way 9186 3
...Albuferon(R) for hepatitis C and LymphoStat-B(R) f...ial launch in 2010 -,- ABthrax(TM) for inhalation ...- Pipeline strengthened with investments in oncolo...ets initiative - - GSK to advance darapladib ... May 28 Human Genome Sciences,Inc. (Nasdaq: HGSI...
...rst Phase III study performed solely in high risk ...ovement in Disease Free Survival (DFS), BRIDGEWAT... Espanol de Investigacion en Cancer de Mama) annou...tive early stage breast cancer,adjuvant treatment ...ion,Concentrate as part of the TAC regimen (Taxote...
Other Medicine Technology:Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 2Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 3Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 4Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 5Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 6Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 7Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 8Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 9Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 10Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 11Node-Negative Early Stage Breast Cancer Patients Benefit from Taxotere(R)-Based Chemotherapy 2Node-Negative Early Stage Breast Cancer Patients Benefit from Taxotere(R)-Based Chemotherapy 3Node-Negative Early Stage Breast Cancer Patients Benefit from Taxotere(R)-Based Chemotherapy 4Node-Negative Early Stage Breast Cancer Patients Benefit from Taxotere(R)-Based Chemotherapy 5
(Date:11/8/2009)... AARP Praises House Passage of Health Care Reform...n Medicare, improve coverage for all Americans ,...SUMMARY: Tonight the United States House of Repre...slation that would strengthen Medicare for seniors...t prices millions of Americans out of affordable h...
(Date:11/7/2009)... WASHINGTON , Nov. 7 ...ay in support of H.R. 3962, the Affordable Health ...legislation later tonight. Below are the Speaker,... know, is an historic moment for our nation and fo...s of every party and political philosophy -- as fa...
(Date:11/7/2009)... Jacquelyn T. Coleman (CT), David A. Cook (GA), L...L. Tarver (LA) Honored ,, CHICAGO, Nov. 7 /PRN...ation (AMA) today presented five medical society e...their contributions to the goals and ideals of the...the AMA,s semi-annual policy making meeting in Hou...
(Date:11/7/2009)... WASHINGTON, Nov. 7 Wit...g, antichoice extremists are holding the entire bi...hey are demanding that the bill go far beyond the ...incorporated into the original bill. In an outrag...arly Saturday afternoon, antichoice Democrats are ...
(Date:11/7/2009)... WASHINGTON, Nov. 7 Spe...ess availability this afternoon following a Democr...on Caucus Room. Below are the Speaker,s opening r...s, it was a great occasion for us to receive the P...will be making history with our vote and making pr...
Breaking Medicine News(10 mins):Health News:AARP Maryland Key Vote News Alert 2Health News:AARP Maryland Key Vote News Alert 3Health News:Pelosi: Health Legislation Founded on Key Principles for a Healthier America: Innovation, Competition and Prevention 2Health News:Pelosi: Health Legislation Founded on Key Principles for a Healthier America: Innovation, Competition and Prevention 3Health News:Pelosi: Health Legislation Founded on Key Principles for a Healthier America: Innovation, Competition and Prevention 4Health News:AMA Honors Medical Society Executives 2Health News:Pelosi Remarks Following House Democrats' Meeting with President Obama 2
...nd Earnings per Share for the Year, CHICAGO, Feb....software, connectivity and information solutions t...nounced results for the three,months and year ende... 2007 was $73.4,million, compared to $63.6 million...
... Eye Institute (NEI) and the Food and Drug Adminis...er new disease-relevant outcome measures appropria..., clinical drug trials for glaucoma therapies rely...alities and changes in the optic nerve structure a...
...rnor Edward G.,Rendell today received a blueprint ...nia billions of dollars as the commonwealth become...ays for treatment of chronic diseases,while signif... part of the,Governor,s Prescription for Pennsylva...
...nior Living Inc.,(NYSE: BKD ) announced today tha...year 2007 financial results after the market close...scheduled a conference call to discuss,the results...side of the U.S.) ten minutes prior to the schedul...
...Feb. 13 Quintiles,Transnational Corp. today annou... certified by the College of American Pathologists...ng clinical trials in the first,quarter of 2007. T... commitment to providing high-quality,central labo...
...February 13, 2008) -- Sanofi Pasteur, the vaccines...he first application in Europe to deliver a vaccin...system developed by BD (Becton, Dickinson and Comp...fi Pasteur conducted clinical trials on more than ...
Other Medicine News:Health News:Allscripts Reports Fourth Quarter 2007 Results 2Health News:Allscripts Reports Fourth Quarter 2007 Results 3Health News:Allscripts Reports Fourth Quarter 2007 Results 4Health News:Allscripts Reports Fourth Quarter 2007 Results 5Health News:Allscripts Reports Fourth Quarter 2007 Results 6Health News:Allscripts Reports Fourth Quarter 2007 Results 7Health News:Allscripts Reports Fourth Quarter 2007 Results 8Health News:Allscripts Reports Fourth Quarter 2007 Results 9Health News:Allscripts Reports Fourth Quarter 2007 Results 10Health News:Upcoming meeting will explore new technologies for glaucoma clinical drug trials 2Health News:PA Governor Rendell Says Pennsylvania Again Leads the Nation With Introduction of Chronic Care Management Plan 2Health News:PA Governor Rendell Says Pennsylvania Again Leads the Nation With Introduction of Chronic Care Management Plan 3Health News:PA Governor Rendell Says Pennsylvania Again Leads the Nation With Introduction of Chronic Care Management Plan 4Health News:Brookdale Announces Fourth Quarter and Full Year 2007 Release and Earnings Call 2Health News:Quintiles Central Laboratory in India Receives CAP Certification 2Health News:1st EMEA application filed for product using innovative intradermal microinjection system BD Soluvia 2
Alger Brush Mk II
Diamond Burr 5.0mm (5086)
Ophthalmic Burr
Khosla Non-Illuminated Trial Lens Set, With Lenses Mounted
Medicine Products: